Discontinuations for branaplam, iptacopan and Piqray could increase pipeline scepticism, but more pruning is coming.
The plug is pulled on a deal with J&J, and Fate swings the axe over its staff and NK cell pipeline.
Will biotech lead a bull market recovery? Will Novartis spin off its cell therapy business? Read on for some of your leftfield predictions for biopharma.
The chocolate-to-vitamins giant discovers that launching a drug is hard. Should its biopharma partners be worried?
As the company pulls Blenrep, questions about its future will only intensify.
Astra’s stealthy move into cell therapy has yielded a truly novel cancer target, and the company could be in clinical trials soon.